In the base year, the Europe proteomics market was worth USD 5,356 million. By the end of the forecast period, it is expected to record a CAGR of 12.4% which is worth USD 10,793 million.
The COVID-19 pandemic turned the spotlight on proteomic studies, and thus, it is expected to drive the studied market growth during the present crisis. According to an article published in the International Journal of Molecular Sciences in March 2022, it has been observed that omics-based technologies were largely adopted during the COVID-19 pandemic. The omic technology could be applied at every level of application, from the detection of mutations, methods of diagnosis or monitoring, drug target discovery, and vaccine generation, to the basic definition of the pathophysiological processes and the biochemical mechanisms behind the infection and spread of SARS-CoV-2. Proteomics aids in the identification of novel biomarkers of the SARS-CoV-2 virus and thus provides effective opportunities for point-of-care clinical healthcare delivery in the most cost-effective manner. Thus, the wide application of proteomics in developing therapeutics for coronavirus has impacted market growth during a pandemic. Moreover, the rising adoption of proteomics technology by pharmaceutical companies and the increasing demand for personalized medicines also increased market growth and are expected to continue over the forecast period.
Factors such as the rising demand for personalized medicine, increasing research and expenditure, and government funding for proteomics, as well as technological advancements, are boosting the market's growth.
Proteomics has received great attention over the last decade, particularly in the fields of diagnosis, drug research, and drug development. It has various applications, ranging from the identification of proteins to the purification and separation of the proteins to study their nature and properties. It has numerous applications in identifying protein-related disorders or diseases in the body.Thus, it is evolving into an important tool in the field of life sciences.
Furthermore, increasing demand for personalized medicine in Europe, along with the presence of key market players such as Merck KGaA, is expected to boost regional growth. Also, positive support from the local authorities in Europe and initiatives by research organizations to advance proteomics technologies such as chemoproteomics and spectrometry are expected to further fuel market growth. For example, Biognosys, a Swiss company, will launch Spectronaut 16 and present major scientific and technological advances of its proprietary proteomics research services at the American Society for Mass Spectrometry (ASMS) Annual Conference in May 2022.
Similarly, in February 2021, the international metaproteomics community launched the Metaproteomics Initiative to promote the dissemination of metaproteomics fundamentals, advancements, and applications through collaborative networking in microbiome research.
Therefore, owing to the aforementioned factors, the studied market is expected to grow over the forecast period. The high cost of instruments, on the other hand, is likely to slow the growth of the proteomics market in Europe over the next few years.
The growing burden of chronic diseases is the key factor driving demand for effective drugs, which is boosting segment growth. For instance, as per 2022 statistics published by the IDF, about 6.1 million people were living with diabetes in Germany in 2021, and this number is projected to reach 6.5 million by 2030. Thus, the expected increase in the diabetic population is expected to increase the demand for personalized treatment. This is anticipated to fuel the demand for proteomics, for investigating the set of proteins within different tissues of diabetic patients, over the forecast period, hence bolstering the segment's growth.
The discovery of new and effective therapies for the treatment of disease is considered one of the most ongoing developments in the study of human genes and proteins. This way of finding proteins that are linked to diseases and making new medicines is based on genome and proteome data, which are then used to find new therapeutic targets by using software technologies.
Furthermore, the rising company activities in developing advanced mass spectrometry instruments to help pharmaceutical and biopharmaceutical companies develop drugs are also contributing to segment growth. For instance, in September 2022, Thermo Fisher Scientific Inc. will launch a new mass spectrometry instrument, the Thermo Scientific Orbitrap Ascend Tribrid mass spectrometer, at the International Mass Spectrometry Conference (IMSC) in the Netherlands. The instrument offers new capabilities for multiplexed proteomics and native protein characterization as well as improved sample throughput, versatility, and ease of use, all while producing high-quality data with simplicity.
Furthermore, the growing company's efforts to develop and expand its proteomics portfolio and offering are contributing to segment growth.For instance, in March 2022, Olink Holdings AB collaborated with TATAA Biocenter to launch the Olink Explore 3072 proteome profiling service. With this collaboration, the company increases its capacity to offer workflow optimizations and validations, including multi-omics. The TATAA Biocenter also uses the Olink technology for proteomics analysis in the European Union-funded projects for identifying molecular mechanisms of pain-related disorders and combining optoacoustic imaging phenotypes and multi-omics to advance diabetes healthcare.
Thus, due to the aforementioned factors, such as the rising burden of diabetes and increasing company activities such as launching advanced mass spectrometry instruments, the studied segment is expected to grow over the forecast period.
The rising burden of chronic diseases such as cancer, cardiovascular diseases, respiratory diseases, chronic kidney diseases, and others is the key factor driving the growth of the proteomics market. For instance, according to 2022 statistics published by the National Health Service, about 1.17 million people in England were diagnosed with chronic obstructive pulmonary disorder (COPD) in 2020-2021, accounting for 1.9% of the total population. Also, as per the GLOBOCAN report, an estimated 596,000 new cancer cases are expected to be diagnosed in the United Kingdom by 2040.
Additionally, as per the British Heart Foundation's England Factsheet, published in January 2022, about 6.4 million people were living with cardiovascular diseases in England in 2021. Also, as per the data published by the NHS, in September 2021, more than 2 million people will experience arrhythmias or heart rhythm problems every year in the United Kingdom. The high burden of cardiovascular diseases among the population can lead to atrial fibrillation and arterial thrombosis, increasing the demand for personalized medicines, which in turn is anticipated to fuel market growth over the forecast period.
Furthermore, rising healthcare spending as well as rising R&D expenditures hasten the development of advanced and effective drugs as well as drug development tools.This is also contributing to market growth. For example, according to OECD data, the United Kingdom spent EUR 277 million (USD 291.7 million) on healthcare activities in 2021, a 7.4% increase over the previous year.Also, as per the 2021 data published by the United Kingdom Government, about EUR 5 billion (USD 5272 billion) was spent on pharmaceutical research in the United Kingdom, and this number is anticipated to increase by 2030.
Moreover, the growing adoption of various business strategies, such as acquisition, collaboration, and others, by the companies is also expected to increase the demand for proteomics drugs and services, thereby fueling market growth in the United Kingdom. For instance, in November 2022, RxCelerate acquired Methuselah Health UK Ltd. Through this acquisition, the company is providing a next-generation proteomics technology, ProQuant, which can better quantify post-translational modifications, including proteolytic cleavages, in complex protein mixtures and opens up a new domain for target identification and validation, biomarker discovery, and reaction monitoring.
Therefore, owing to the aforementioned factors such as the rising prevalence of chronic diseases, increasing healthcare and research and development spending, and growing company activities, the studied market is expected to grow in the United Kingdom over the forecast period.
This product will be delivered within 2 business days.
The COVID-19 pandemic turned the spotlight on proteomic studies, and thus, it is expected to drive the studied market growth during the present crisis. According to an article published in the International Journal of Molecular Sciences in March 2022, it has been observed that omics-based technologies were largely adopted during the COVID-19 pandemic. The omic technology could be applied at every level of application, from the detection of mutations, methods of diagnosis or monitoring, drug target discovery, and vaccine generation, to the basic definition of the pathophysiological processes and the biochemical mechanisms behind the infection and spread of SARS-CoV-2. Proteomics aids in the identification of novel biomarkers of the SARS-CoV-2 virus and thus provides effective opportunities for point-of-care clinical healthcare delivery in the most cost-effective manner. Thus, the wide application of proteomics in developing therapeutics for coronavirus has impacted market growth during a pandemic. Moreover, the rising adoption of proteomics technology by pharmaceutical companies and the increasing demand for personalized medicines also increased market growth and are expected to continue over the forecast period.
Factors such as the rising demand for personalized medicine, increasing research and expenditure, and government funding for proteomics, as well as technological advancements, are boosting the market's growth.
Proteomics has received great attention over the last decade, particularly in the fields of diagnosis, drug research, and drug development. It has various applications, ranging from the identification of proteins to the purification and separation of the proteins to study their nature and properties. It has numerous applications in identifying protein-related disorders or diseases in the body.Thus, it is evolving into an important tool in the field of life sciences.
Furthermore, increasing demand for personalized medicine in Europe, along with the presence of key market players such as Merck KGaA, is expected to boost regional growth. Also, positive support from the local authorities in Europe and initiatives by research organizations to advance proteomics technologies such as chemoproteomics and spectrometry are expected to further fuel market growth. For example, Biognosys, a Swiss company, will launch Spectronaut 16 and present major scientific and technological advances of its proprietary proteomics research services at the American Society for Mass Spectrometry (ASMS) Annual Conference in May 2022.
Similarly, in February 2021, the international metaproteomics community launched the Metaproteomics Initiative to promote the dissemination of metaproteomics fundamentals, advancements, and applications through collaborative networking in microbiome research.
Therefore, owing to the aforementioned factors, the studied market is expected to grow over the forecast period. The high cost of instruments, on the other hand, is likely to slow the growth of the proteomics market in Europe over the next few years.
Europe Proteomics Market Trends
The Drug Discovery Segment is Expected to Have a Notable Growth Rate over the Forecast Period in Europe
The drug discovery segment is expected to witness significant growth in the proteomics market over the forecast period owing to factors such as the rising prevalence of chronic diseases such as cancer, cardiovascular diseases, respiratory diseases, chronic kidney diseases, and others, the increasing adoption of personalized medicines, and the growing utilization of proteomics for developing drugs. Furthermore, rising spending on drug discovery and development by pharmaceutical and biopharmaceutical companies, as well as research organizations in the region, is the primary driver of segment growth over the forecast period.The growing burden of chronic diseases is the key factor driving demand for effective drugs, which is boosting segment growth. For instance, as per 2022 statistics published by the IDF, about 6.1 million people were living with diabetes in Germany in 2021, and this number is projected to reach 6.5 million by 2030. Thus, the expected increase in the diabetic population is expected to increase the demand for personalized treatment. This is anticipated to fuel the demand for proteomics, for investigating the set of proteins within different tissues of diabetic patients, over the forecast period, hence bolstering the segment's growth.
The discovery of new and effective therapies for the treatment of disease is considered one of the most ongoing developments in the study of human genes and proteins. This way of finding proteins that are linked to diseases and making new medicines is based on genome and proteome data, which are then used to find new therapeutic targets by using software technologies.
Furthermore, the rising company activities in developing advanced mass spectrometry instruments to help pharmaceutical and biopharmaceutical companies develop drugs are also contributing to segment growth. For instance, in September 2022, Thermo Fisher Scientific Inc. will launch a new mass spectrometry instrument, the Thermo Scientific Orbitrap Ascend Tribrid mass spectrometer, at the International Mass Spectrometry Conference (IMSC) in the Netherlands. The instrument offers new capabilities for multiplexed proteomics and native protein characterization as well as improved sample throughput, versatility, and ease of use, all while producing high-quality data with simplicity.
Furthermore, the growing company's efforts to develop and expand its proteomics portfolio and offering are contributing to segment growth.For instance, in March 2022, Olink Holdings AB collaborated with TATAA Biocenter to launch the Olink Explore 3072 proteome profiling service. With this collaboration, the company increases its capacity to offer workflow optimizations and validations, including multi-omics. The TATAA Biocenter also uses the Olink technology for proteomics analysis in the European Union-funded projects for identifying molecular mechanisms of pain-related disorders and combining optoacoustic imaging phenotypes and multi-omics to advance diabetes healthcare.
Thus, due to the aforementioned factors, such as the rising burden of diabetes and increasing company activities such as launching advanced mass spectrometry instruments, the studied segment is expected to grow over the forecast period.
United Kingdom is Expected to Have the Significant Market Share Over the Forecast Period
The United Kingdom is expected to witness significant growth in the proteomics market over the forecast period. The factors contributing to market growth are the rising prevalence of various chronic diseases, the growing demand for personalized medicines, and emerging technological advancements.The rising burden of chronic diseases such as cancer, cardiovascular diseases, respiratory diseases, chronic kidney diseases, and others is the key factor driving the growth of the proteomics market. For instance, according to 2022 statistics published by the National Health Service, about 1.17 million people in England were diagnosed with chronic obstructive pulmonary disorder (COPD) in 2020-2021, accounting for 1.9% of the total population. Also, as per the GLOBOCAN report, an estimated 596,000 new cancer cases are expected to be diagnosed in the United Kingdom by 2040.
Additionally, as per the British Heart Foundation's England Factsheet, published in January 2022, about 6.4 million people were living with cardiovascular diseases in England in 2021. Also, as per the data published by the NHS, in September 2021, more than 2 million people will experience arrhythmias or heart rhythm problems every year in the United Kingdom. The high burden of cardiovascular diseases among the population can lead to atrial fibrillation and arterial thrombosis, increasing the demand for personalized medicines, which in turn is anticipated to fuel market growth over the forecast period.
Furthermore, rising healthcare spending as well as rising R&D expenditures hasten the development of advanced and effective drugs as well as drug development tools.This is also contributing to market growth. For example, according to OECD data, the United Kingdom spent EUR 277 million (USD 291.7 million) on healthcare activities in 2021, a 7.4% increase over the previous year.Also, as per the 2021 data published by the United Kingdom Government, about EUR 5 billion (USD 5272 billion) was spent on pharmaceutical research in the United Kingdom, and this number is anticipated to increase by 2030.
Moreover, the growing adoption of various business strategies, such as acquisition, collaboration, and others, by the companies is also expected to increase the demand for proteomics drugs and services, thereby fueling market growth in the United Kingdom. For instance, in November 2022, RxCelerate acquired Methuselah Health UK Ltd. Through this acquisition, the company is providing a next-generation proteomics technology, ProQuant, which can better quantify post-translational modifications, including proteolytic cleavages, in complex protein mixtures and opens up a new domain for target identification and validation, biomarker discovery, and reaction monitoring.
Therefore, owing to the aforementioned factors such as the rising prevalence of chronic diseases, increasing healthcare and research and development spending, and growing company activities, the studied market is expected to grow in the United Kingdom over the forecast period.
Europe Proteomics Market Competitor Analysis
The European proteomics market is moderately consolidated and consists of a few major players. Companies like Agilent Technologies Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Merck KGaA, Promega Corporation, Thermo Fisher Scientific Inc., and Waters Corporation are key players, among others. The companies are involved in various strategies, such as new product launches and investments in research and development activities, to sustain themselves in the highly competitive environment.Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Waters Corporation
- Promega Corporation
- Merck KGaA
- Bruker Corporation
- DiaSorin S.p.A (Luminex Corporation)
- PerkinElmer Inc.
- Sengenics
- Horiba Ltd
- Creative Proteomics
- Becton, Dickinson and Company
Methodology
LOADING...
